NovoCure Limited (NVCR) IPO Opens Lower
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
NovoCure (NVCR) Launches 12.5M Common Stock IPO
October 2, 2015 6:09 AM EDTNovoCure Limited (Nasdaq: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today the launch of its initial public offering of 12,500,000 shares of its common stock, including 7,500,000 shares to be sold by NovoCure Limited and 5,000,000 shares to be sold by selling shareholders. The initial public offer is currently expected to be between $26 and $29 per share. The underwriters for the offering will... More
NovoCure (NVCR) Trims IPO Expectations
October 1, 2015 2:10 PM EDTNovoCure Ltd. (Nasdaq: NVCR) filed an amended registration with the U.S. SEC today. The company now plans to offer 7.5 million ordinary shares and sees an offering price of $23 - $24 per share, from prior expectations of offering 12.5 million shares with an expected pricing... More
